NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer

Journal of Thoracic Oncology - Tập 9 Số 3 - Trang 410-413 - 2014
Peter Ellis1, Frances A. Shepherd2, Scott A. Laurie3, Glenwood D. Goss3, Martin Olivo4, Jean Powers4, Lesley Seymour4, Penelope Ann Bradbury4
1Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton Ontario, Canada
2Medical Oncology Department, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
3Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada
4NCIC CTG Queens University, Kingston, Ontario, Canada

Tóm tắt

Từ khóa


Tài liệu tham khảo

American Cancer Society, 2012

Shepherd, 2007, The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer, J Thorac Oncol, 2, 1067, 10.1097/JTO.0b013e31815bdc0d

Chute, 1999, Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress, J Clin Oncol, 17, 1794, 10.1200/JCO.1999.17.6.1794

Feld, 1987, Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung, J Clin Oncol, 5, 1401, 10.1200/JCO.1987.5.9.1401

Murray, 1999, Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group, J Clin Oncol, 17, 2300, 10.1200/JCO.1999.17.8.2300

Niell, 2005, Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732, J Clin Oncol, 23, 3752, 10.1200/JCO.2005.09.071

Humblet, 1987, Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study, J Clin Oncol, 5, 1864, 10.1200/JCO.1987.5.12.1864

Blackhall, 2007, Small cell lung cancer and targeted therapies, Curr Opin Oncol, 19, 103, 10.1097/CCO.0b013e328011bec3

Quinn, 1996, Insulin-like growth factor expression in human cancer cell lines, J Biol Chem, 271, 11477, 10.1074/jbc.271.19.11477

Izycki, 2006, Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy, Oncol Res, 16, 49, 10.3727/000000006783981251

Scartozzi, 2010, Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer, Curr Opin Mol Ther, 12, 361

Jassem, 2010, Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC), ASCO Meeting Abstracts, 28, 7500

Arnold, 2007, J Clin Oncol, 25, 4278, 10.1200/JCO.2007.12.3083

Lee, 2007, A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC): PRS-04, J Thor Oncol, 2, S306, 10.1097/01.JTO.0000283089.56099.79

Langer, 2011, A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC), ASCO Meeting Abstracts, 29, 7001